Complete androgen blockade in prostate cancer. Organizing an overview.
The value of the addition of a pure antiandrogen to castration in advanced prostate cancer will be evaluated by an overview of all randomized studies addressing this question. This overview is currently being organized. Care is taken on identifying all randomized studies, published or unpublished, to avoid publication bias. Already 15 studies possibly related to the question are under investigation. Principal investigators of each relevant study are invited to participate in the overview. The principal end points of the study are overall and cause-specific mortality. The first report of results is planned for the end of 1991.
Department of Tumor Registration, Epidemiology and Clinical Trials, The Netherlands Cancer Institute, Amsterdam.
O
O
Dalesio
D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
D000726:Androgen Antagonists